Clinical trials: Antiviral Agents
Chronic Hepatitis B
Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection
Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will show effective antiviral activity and prevent further development of antiviral resistance in hepatitis B e antigen(HBeAg)-positive or -negative Chronic…
- Trial name
- NCT01594905
- Testing
- Entecavir + Tenofovir (MDR group)
- Volunteers
- 90 people
- Sponsor
- Yonsei University
Infection, Human Immunodeficiency Virus I, HIV Infection
GW873140 In Combination With Kaletra In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
- Trial name
- NCT00102778
- Testing
- GW873140, Kaletra (lopinavir/ritonavir)
- Where
- 70 sites in United States, Canada and 8 more
- Volunteers
- 175 people
- Sponsor
- ViiV Healthcare
Lymphoma, Chronic Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral…
- Trial name
- NCT02056548
- Volunteers
- 126 people
- Sponsor
- Seoul St. Mary's Hospital
Hepatitis C Virus
Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine
The project will evaluate cost and treatment outcomes of a simplified Hepatitis C Virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations in Ukraine.
- Trial name
- NCT04038320
- Testing
- Sofosbuvir/ledipasvir (SOF/LDV)
- Where
- 2 sites in Ukraine
- Volunteers
- 868 people
- Sponsor
- Right to Care
HBV Infection, Pregnancy
"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral…
- Trial name
- HIPOCAMP (NCT07054359)
- Testing
- HBsAg RDT Women, Treatment by TDF if HBcrAg RDT positive, Treatment by TDF
- Where
- Vietnam
- Volunteers
- 3,200 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults
To investigate safety, tolerability and antiviral activity in Non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced HIV-1 infected patients
- Trial name
- NCT00090077
- Testing
- GW695634
- Where
- 18 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but…
- Trial name
- NCT02275065
- Testing
- Bictegravir
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gilead Sciences
Hepatitis C Infection, Thrombocytopenia
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
- Trial name
- NCT01153919
- Testing
- romiplostim, ribavirin, PEG-interferon alfa-2a
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Influenza
Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.
- Trial name
- NCT02423577
- Testing
- FF-3 dry powder
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
HIV Infections
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3.
- Trial name
- NCT00000692
- Testing
- Butyldeoxynojirimycin
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- G D Searle
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Hepatitis C, Chronic
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
The objective of this trial is to investigate tolerability, safety, pharmacokinetics and antiviral activity of BI 207127 NA in combination with BI 201335 NA and ribavirin for 8 weeks in Japanese treatment-naive patients with…
- Trial name
- NCT01528735
- Testing
- BI 207127 NA, peginterferon, Ribavirin
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of…
- Trial name
- SPIRITUS (NCT02367313)
- Testing
- Vapendavir
- Where
- 62 sites in United States, Bulgaria and 4 more
- Volunteers
- 455 people
- Sponsor
- Biota Pharmaceuticals, Inc.
HBV, Chronic Hepatitis b
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced…
- Trial name
- NCT06926647
- Testing
- Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα
- Where
- 85 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing 302 Hospital
BKV Infection, EBV Infection
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after…
- Conditions
- BKV Infection, EBV Infection, CMV Infection
- Trial name
- NCT07670468
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- LucasBio
Chronic Hepatitis C Infection
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
The purpose of this 3-part study is to evaluate the potential impact of simeprevir and food on pharmacokinetics (PK) of IDX719 in healthy participants. Part 1 will evaluate potential PK interactions between IDX719 and simeprevir.
- Trial name
- NCT01813513
- Testing
- IDX719, Simeprevir
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give 1592U89 plus 141W94 plus DMP 266 to patients with HIV who have developed resistance to indinavir, ritonavir, saquinavir, or nelfinavir after at least 20…
- Trial name
- NCT00002213
- Testing
- Abacavir sulfate, Amprenavir, Efavirenz
- Where
- 9 sites in United States
- Volunteers
- 80 people
- Sponsor
- Glaxo Wellcome
Hepatitis B Virus (HBV)
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT00734162
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- 21 sites in United States, Bulgaria and 5 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Respiratory Syncytial Virus (RSV)
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
- Trial name
- NCT02534350
- Testing
- Presatovir
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.